Characterization of ERBB2 alterations in non-small cell lung cancer.

Vijendra Singh,Rebecca Feldman,Ammar Sukari,Chul Kim,Hirva Mamdani,Alexander I. Spira,Gerold Bepler,Edward S. Kim,Luis E. Raez,Sachin Gopalkrishna Pai,Chukwuemeka Ikpeazu,Ari M. Vanderwalde,Joanne Xiu,Antoinette J Wozniak,Hossein Borghaei,Stephen V. Liu,Misako Nagasaka

Characterization of ERBB2 alterations in non-small cell lung cancer.

2020

Vijendra Singh
Rebecca Feldman
Ammar Sukari
Chul Kim
Hirva Mamdani
Alexander I. Spira
Gerold Bepler
Edward S. Kim
Luis E. Raez
Sachin Gopalkrishna Pai
Chukwuemeka Ikpeazu
Ari M. Vanderwalde
Joanne Xiu
Antoinette J Wozniak
Hossein Borghaei
Stephen V. Liu
Misako Nagasaka

e21553Background: ERBB2 alteration (mutation and/or amplification) is associated with poor survival in non-small cell lung cancer (NSCLC) and is commonly reported as a resistance mechanism to EGFR ...

Keywords:

Lung cancer
non small cell
Pathology
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations